Skip to main content
F1000Research logoLink to F1000Research
. 2016 Mar 17;5:F1000 Faculty Rev-366. [Version 1] doi: 10.12688/f1000research.7431.1

Metals and Neurodegeneration

Pan Chen 1,a, Mahfuzur Rahman Miah 1, Michael Aschner 1,b
PMCID: PMC4798150  PMID: 27006759

Abstract

Metals play important roles in the human body, maintaining cell structure and regulating gene expression, neurotransmission, and antioxidant response, to name a few. However, excessive metal accumulation in the nervous system may be toxic, inducing oxidative stress, disrupting mitochondrial function, and impairing the activity of numerous enzymes. Damage caused by metal accumulation may result in permanent injuries, including severe neurological disorders. Epidemiological and clinical studies have shown a strong correlation between aberrant metal exposure and a number of neurological diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis, autism spectrum disorders, Guillain–Barré disease, Gulf War syndrome, Huntington’s disease, multiple sclerosis, Parkinson’s disease, and Wilson’s disease. Here, we briefly survey the literature relating to the role of metals in neurodegeneration.

Keywords: metal accumulation, neurological disorders, Alzheimer’s disease, neurodegeneration, Huntington’s disease, Parkinson’s disease

Introduction

Metals are a component of the earth’s crust and exist in the water, air, and a variety of ecosystems. They can generally be divided into two groups: essential and non-essential metals. Essential metals include chromium, cobalt, copper (Cu), iron (Fe), lithium, magnesium, manganese (Mn), nickel, selenium, and zinc (Zn). These trace metals usually act as a cofactor of enzymes to regulate cellular activities. For example, Mn is required for the activity of arginase, hydrolases, lyases, glutamine synthetase, and superoxide dismutase (SOD) 1. Thus, these metals are involved in a whole host of physiological processes, such as electron transport, oxygen transportation, protein modification, neurotransmitter synthesis 2, 3, redox reactions, immune responses, cell adhesion, and protein and carbohydrate metabolism 1, to name a few. Metals accumulate in the brain, indicating their important roles in the nervous system. Deficiency of these metals has been associated with various neurological diseases. For example, Fe deficiency is related to restless leg syndrome, pediatric stroke, breath-holding spells, pseudotumor cerebri, and cranial nerve palsy 4, 5.

Although metals are important for animals and plants, they usually are required in trace amounts. Excessive metal levels accumulate in various organs, including the brain. Elevated levels of metals may induce various detrimental intracellular events, including oxidative stress, mitochondrial dysfunction, DNA fragmentation, protein misfolding, endoplasmic reticulum (ER) stress, autophagy dysregulation, and activation of apoptosis 613. These effects may alter neurotransmission and lead to neurodegeneration, which can manifest as cognitive problems, movement disorders, and learning and memory dysfunction. To date, metal-induced neurotoxicity has been associated with multiple neurological diseases in humans, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), autism spectrum disorders (ASDs), Guillain–Barré disease (GBD), Gulf War syndrome (GWS), Huntington’s disease (HD), manganism, multiple sclerosis, Parkinson’s disease (PD), and Wilson’s disease (WD) 3, 1418. Here, we address the neurotoxicity of several metals as well as the human neurological diseases associated with these metals.

Essential metals

Copper

Cu is an essential trace element and a transition metal required for physiological activities in mammals. Cu acts as a cofactor of various enzymes (such as cytochrome c oxidase and SODs), playing an important role in electron transport, oxygen transportation, protein modification, and neurotransmitter synthesis 2, 3. However, elevated Cu levels may result in the generation of reactive oxygen species (ROS), DNA damage, and mitochondrial dysfunction 3. Excessive Cu has been associated with AD, ALS, HD, PD, WD, and prion diseases in humans 3, 16, 19. Cu may enhance the self-aggregation of amyloid precursor proteins and β-amyloid peptide 20, and increased levels of Cu in cerebrospinal fluid have been found in some patients with AD 21. Similarly, Cu interacts with α-synuclein and promotes its aggregation, which could result in PD 22. Gain-of-function mutations in Cu/Zn-SOD might result in oxidative stress through production of free radicals, possibly leading to motor neuron degeneration in patients with ALS 3, 21. It is also noteworthy that metals such as Cu and Zn are controlled by overlapping proteins, such as metallothionein 23. Notably, Cu levels are also higher in HD patients compared with controls 24.

Prion diseases are characterized by altered structure, changing from a normal cellular isoform (PrP C) to an abnormal scrapie isoform (PrP Sc), which contains high-affinity Cu-binding sites. The binding of Cu enhances the stability of prion proteins, making them resistant to proteasomal degradation and leading to neurodegeneration 3. However, the binding capability of Cu to the prions does not explain its role in the progression of prion disease. It is noteworthy that metal mixtures, such as silver and Cu, have been shown to change the affinity of PrP C to Cu 19. In addition, an inverse correlation between Cu and Mn has been noted in patients with prion disease 25, 26. Cu does not appear in the formation of PrP Sc, and increases in Cu in the diet have been associated with delays in the onset of prion disease 2729. Given both the beneficial and neurotoxic effect of Cu in the brain, new biomarkers and improved measurement of Cu trafficking are needed to predict potential risks, and novel therapeutics need to be developed for Cu-induced neurotoxicity and cognitive dysfunction.

Iron

Fe is an essential metal, serving as a cofactor for a variety of enzymes and proteins, most prominently hemoglobin 30. Fe’s ability to interact with oxygen makes it important for oxygen transport in the cellular respiration pathway as well as for a variety of redox reactions 31. Exposure to Fe is primarily through food consumption, although toxic levels of Fe accumulation are usually due to disrupted Fe homeostasis and metabolism in the brain 32, 33. Hemolysis, the breakdown of red blood cells, in the young brain with an immature blood-brain barrier (BBB) can also lead to aberrant Fe accumulation, which results in neuronal damages 34. Fe accumulation can cause increased ROS levels, lipid peroxidation, protein oxidation, DNA damage, dopamine autoxidation, and mitochondrial fragmentation 3538.

Fe dyshomeostasis has been linked to a variety of neurological disorders, including PD, AD, HD, ALS, and neurodegeneration with brain iron accumulation (NBIA) 36, 3942. Increased brain Fe deposition has been observed and Fe has been shown to promote aggregation of α-synuclein, which is found in patients with PD 4345. Increased Fe accumulation in the brains of patients with AD has also been observed along with evidence of Fe contributing to β-amyloid aberrant aggregation and toxicity, a hallmark of the disease 4648. Increased Fe is also seen in patients with HD, and Huntingtin (htt), the central protein in HD pathology, is thought to mediate Fe homeostasis 49, 50. Patients with ALS show accumulation of Fe in the motor cortex, and SOD-1, a gene mutated in patients with ALS, has been shown to cause damage via Fe-induced oxidative stress 5154. Finally, NBIA, as the name implies, is an umbrella of heterogeneous neurodegenerative diseases that present with simultaneous Fe accumulation. Genetic studies indicate that the majority of the genes mutated in patients with NBIA are related not to Fe homeostasis but rather to autophagy, mitochondria metabolism, and lipid metabolism. This suggests that Fe accumulation in patients with NBIA may not be the initial insult of a disease pathology but rather a downstream phenomenon that serves to exacerbate already-present issues 41. Alternatively, these genes may have currently unknown Fe regulatory functions that have yet to be examined. This question of whether Fe is part of the cause of a disease, or vice versa, continues to be a point of controversy.

Manganese

Mn is a trace element and nutrient necessary for biological processes within the human body 55. Low concentrations of Mn are essential to the body; Mn serves as a cofactor in a variety of metalloproteins, including MnSOD and arginase, and is important in the function of a variety of enzymes, including glutamine synthetase, hydrolases, and lyases 55, 56. Exposure to high levels of Mn may be toxic. Consumption of food is the primary route for entrance into the body 56, 57. Mn can be inhaled as well, and this serves as an occupational hazard for those who work in welding and mining industries 1, 58, 59. Soy-based infant formula has been suggested as an exposure route for excess Mn, which may lead to mild neurological defects during critical stages of development 60, 61. Chronic Mn exposure can cause debilitating neurological effects. Mn overexposure leads to a type of parkinsonism known as manganism and has been suggested as part of PD etiology as well 55, 59. Manganism is characterized by tremors, lethargy, and speech impediments, with the occasional accompaniment of psychosis 60, 62. Mn is elevated in dopaminergic (DAergic) neurons of the substantia nigra, providing a possible basis for the motor deficits observed in manganism 63. Elevated Mn has been shown to affect a variety of cellular processes, including increased levels of transcription for ER-related genes 64, ROS production 65, mitochondrial dysfunction 66, autophagy 67, altered acetylcholinesterase (AChE) activity 68, changes in cyclic AMP (cAMP) signaling 69, iron dyshomeostatis 70, and dysfunctional astrocytic activity 61. Many markers of programmed cell death, including increased TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining, internucleosomal DNA cleavage, activation of JNK, p38, the apoptotic initiator caspase-12, and pro-apoptotic effector caspase-3, have been observed in neurons in the presence of Mn exposure 9, 71. Specifically, Mn has been shown to induce proteolytic cleavage of protein kinase C-δ (PKC-δ) as an essential player in Mn-induced neuronal death and in the neuroprotective activity of α-synuclein protein aggregation upon chronic Mn exposure 7274. The induction of apoptosis is possibly mediated through ER stress and autophagy. In DAergic SH-SY5Y cells exposed to Mn, the levels of ER stress response proteins, including the ER chaperone GRP94 and the pro-apoptotic GADD153/CHOP protein, as well as phosphorylated eIF2α (eukaryotic translation initiation factor 2α) are increased significantly 9. In Mn-treated DAergic neurons, increased abnormal lysosomes, decreased expression of autophagy-related protein Beclin1, and activation of mammalian target of rapamycin (mTOR)/p70 ribosomal protein S6 kinase (p70s6k) signaling have been observed, possibly leading to DAergic neurodegeneration 8.

In addition, PD-related mutant genes (such as ATPase 12A3) have been shown to alter Mn homeostasis, supporting the link between Mn dyshomeostasis and PD. Interestingly, the newly identified Mn transporter SLC30A10 has been associated with dystonia, parkinsonism, and hypermanganesemia when mutated 7577. This protein is expressed at high levels in the liver and the basal ganglia 77. Loss-of-function mutants prevent Mn excretion and result in high levels of plasma Mn, which eventually accumulates in the basal ganglia of the brain 75, 77. Indeed, Mn can also catalyze the autoxidation of dopamine, whose toxic metabolites can wreak havoc on DAergic cells, suggestive of similar pathology between PD and manganism 37, 59. In regard to prion disease, a protective role for prion protein against Mn neurotoxicity has been suggested upon short-term exposure to Mn, although prolonged Mn exposure was shown to promote the stabilization and aggregation of the infectious protein 78, 79. Although Mn is an essential metal, Mn homeostatic and signaling pathways are still being delineated, and further investigation may give insight into not only Mn regulation but also manganism and other forms of parkinsonism.

Zinc

Zn is an essential trace metal (the second most abundant transition metal after Fe) required for humans and many other living organisms. It is a cofactor for over 300 enzymes and metalloproteins 80, regulating gene transcription and the antioxidant response. The majority of Zn is in the testes, muscle, liver, and brain 81. In childhood, Zn deficiency affects mental and physical development as well as learning abilities 81, 82. However, excess levels of Zn suppresses Cu and Fe absorption 83, promoting ROS production in the mitochondria, disrupting activities of metabolic enzymes, and activating apoptotic processes 6. Disruption of Zn homeostasis has been associated with AD, brain trauma, cerebral ischemia, epilepsy, and vascular-type dementia (VD) 6, 81. At low concentrations (a few micromolar), Zn suppresses β-amyloid-induced neurotoxicity by selectively precipitating aggregation intermediates 84, 85. However, at high levels, the binding of Zn to β-amyloid may enhance formation of fibrillar β-amyloid aggregation, leading to neurodegeneration 86, 87. Zn also plays a critical role in ischemia-induced neuronal death and the pathogenesis of VD, evidenced by a correlation of increased Zn concentration with glutamate being packaged into synaptic clefts during membrane depolarization under ischemic conditions 81, 88. Future research should assess the intracellular activities of supplemental and neurotoxic Zn in the nervous system and investigate optimal Zn doses needed for different groups of people, especially infants and children.

Non-essential metals

Aluminum

Aluminum (Al) is the third most abundant element and the most abundant metal in the earth’s crust. It has a wide range of uses, including in food preservation, cans, cookware, cars, and vaccine adjuvants, to name a few 14. The exact function of Al in animals remains unknown. Al is highly reactive with carbon and oxygen, making it toxic to living organisms. In humans, Al from dietary intake and environmental exposure is rapidly cleared by the kidney. However, Al salts in vaccine adjuvants remain biologically available and accumulate in the nervous system. Al has been associated with AD, ALS, ASDs, GBD, multiple sclerosis, and GWS in humans 14, 15. In patients with dialysis-associated encephalopathy, Al accumulation was found in the brain together with β-amyloid peptide accumulation 89, 90. Interestingly, the symptoms quickly abated after removal of Al from the dialysis solution 91. Recently, a meta-analysis showed that chronic Al exposure increased the risk of AD by approximately 70% 92. In addition, a correlation between the number of children with ASD and exposure to Al-adjuvanted vaccines was observed 14; higher levels of Al were found in the hair, blood, and urine of children with autism 93. In mice, injection of Al hydroxide results in loss of long-term memory, increased anxiety, and neuronal death in the spinal cord and motor cortex 14. The neurological damage may be due to oxidative stress 12, 13 and mitochondrial dysfunction 9496. However, the results of many of these reports do not address confounding variables such as genetic backgrounds that may predispose an organism to the susceptibility of Al-induced neurological damage. Taken together, genetic polymorphisms combined with environmental factors likely trigger Al-induced neurotoxicity. Future studies could be profitably directed at investigating the relationship between Al exposure and genetic risk factors of these neurological diseases.

Arsenic

Commonly used as a wood preservative in the past and known for its contamination of groundwater, Arsenic (As) is a toxic metalloid and well-known carcinogen, which over 200 million people worldwide are chronically exposed to 97100. Research suggests that As exposure induces mitochondrial oxidative stress, imbalance of intracellular Ca 2+, disruption in ATP production, altered membrane potential, changes in cytoskeletal morphology, and neuronal cell death, among other effects 97, 101. Studies have shown that early-life exposure to As can cause lower brain weight and a reduction in glia and neurons 98. As exposure is associated with AD and ALS 101, 102. Dimethylarsenic acid, a metabolite of As in humans, has been shown to increase β-amyloid levels, a key feature of AD 103. Translocation of neurofilament (NF) was inhibited by As exposure and is linked to decreased NF content at peripheral nerves. This may be important in understanding the aberrant NF distribution that is a hallmark of ALS 104. Owing to the persistent exposure of As to the human population, further investigation into the mechanisms of As poisoning is warranted.

Cadmium

Cadmium (Cd) is a non-essential transition heavy metal and known human carcinogen 105. It can enter the peripheral and central neurons from the nasal mucosa or the olfactory bulb, which damages permeability of the BBB 106. Miners, welders, smokers, and workers in battery production are at risk of high Cd exposure 106. In cells, Cd can induce oxidative stress, suppress gene expression, and inhibit DNA damage repair and apoptosis 107. Chronic exposure to Cd may severely interfere with normal function of the nervous system, and infants and children are more susceptible than adults 106. Cd is a possible etiological factor of neurodegenerative diseases, including AD 108 and PD 17. The symptoms include headache, megrim, olfactory dysfunction, slowing of vasomotor functioning, decreased equilibrium and learning ability, and PD-like symptoms 106. Jiang et al. found that Cd accelerates self-aggregation of Alzheimer’s tau peptide R3 108, and it has been reported in a case study that a 64-year-old man developed PD symptoms 3 months after acute exposure to Cd fumes 17. In zebrafish, Cd exposure resulted in decreased head size and unclear brain subdivision boundaries in the mid-hindbrain region 109. In addition, Cd exposure has been shown to result in morphological changes of rat cortical neurons (axons and dendrites) 110 and inhibited neurite outgrowth in PC12 cells 111. Owing to Cd’s role as a carcinogen, the neurotoxicity induced by Cd is underestimated. Thus, future research should further investigate the mechanism of neurotoxic effect of Cd, especially that of chronic low-level Cd exposure.

Lead

Lead (Pb) is a non-essential heavy metal and a ubiquitously present pollutant in the ecosystem. In humans, inhalation and oral ingestion are the major routes of Pb exposure. In the body, Pb can be excreted in urine and bile, and some Pb can bind to red blood cells and eventually accumulate in bone 112. Pb exposure results in oxidative stress, mitochondrial dysfunction, changes to the Golgi apparatus, and increased gliofilaments in astrocytes 113. It also disrupts Ca 2+ homeostasis 114, interferes with the phosphorylation of PKC 115, and decreases nitric oxide production 116. The main target of Pb-induced toxicity is the nervous system, and children are particularly sensitive to Pb intoxication. The hippocampus is the primary region of Pb accumulation, although the metal may also accumulate in several other brain regions 117. It has been reported that Pb exposure results in deficits in intelligence, memory, executive functioning and attention, processing speed, language, emotion, and visuospatial and motor skills 112. For example, in children, Pb exposure results in decreased intellectual ability in a dose-dependent manner 118, 119, impaired verbal concept formation 120, grammatical reasoning difficulty 121, poor command following 122, and so on. In adults, workers with occupational exposure to Pb have shown impairment of verbal memory and visual memory performance 123, lower decision-making speed 118, deficit in visuomotor coordination 120, and increased interpersonal conflict 124. Given the severe health issues caused by Pb, novel techniques for early diagnosis of Pb exposure (especially during pregnancy and childhood) and effective treatment after Pb exposure should be the focus of future research on Pb.

Methylmercury

Methylmercury (MeHg) is a xenobiotic toxic organic metal compound derived from inorganic mercury (Hg). Hg finds itself in our environment primarily through anthropogenic sources such as industrial waste, coal mining, and natural sources such as volcanoes and forest fires that release Hg back into the atmosphere 125. Hg that pollutes the aquatic arena through these paths can be readily methylated into MeHg by sulfate-reducing bacteria and a variety of other anaerobic bacteria 126. MeHg bioaccumulates in the aquatic food chain, and seafood consumption remains one of the main forms of exposure for humans 127. MeHg has a high affinity for sulfur and can cross the BBB by binding onto thiol groups of proteins; it can also bind to lone cysteine, mimicking the structure of methionine, allowing for the possibility of uptake by amino acid transporters 128, 129. MeHg can accumulate in the brain and has led to epidemics in the past at Minamata Bay and Iraq, where those affected, particularly children, presented with a variety of central nervous system (CNS) disorders, including ataxia, paralysis, retardation, dysarthria, dysesthesia, and cerebral palsy 130. A case study of autopsies in a family that was exposed to high levels of MeHg revealed that exposure to MeHg leads to inorganic Hg buildup in the brain. Furthermore, cerebellar and occipital lobe atrophy was observed in patients who had experienced motor and vision issues. Differential distribution of Hg content was also observed, and the greatest amounts were in the occipital lobe and cerebellum and basal ganglia, reflective of the areas important for vision and movement 131. At the cellular level, MeHg is known to affect a variety of neuronal activities including dopamine metabolism 132, neural stem cell differentiation 133, generation of ROS 134, increased calcium influx 135, aberrant autophagy 136, 137, DNA damage, and mitochondrial dysfunction 138. In addition, MeHg exposure has been shown to increase β-amyloid in the hippocampus and decrease it in the cerebrospinal fluid, both hallmarks of AD 139. Currently, treatment options for those exposed to MeHg are not prevalent. Prevention of exposure has been the major development in the past few decades whereby government advisories have been established to inform and protect their respective populations 140. Limitations on fully understanding the effect of MeHg on the CNS include the confounding beneficial nature of seafood by which MeHg usually enters the human body 141.

Thallium

Thallium (Tl), a naturally occurring trace element, is an extremely toxic heavy metal, sparsely found in the earth’s crust 142, 143. Sources of Tl include industrial processing of cement and non-industrial means such as rodenticide and eating foods from contaminated soils. Tl can make its way into the body not only through consumption but also via the skin and inhalation 142, 144. Non-neurological symptoms include alopecia, hepatic dysfunction, gastroenteritis, and Mees’ lines, and CNS-related disorders include polyneuropathy, cranial nerve deficits, paresthesia, loss of sensation, ataxia, and psychosis 142, 144146. Victims of Tl poisoning complain of peripheral neuropathy 146, 147. It has been shown that Tl exposure can lead to inhibition of AChE, an enzyme catalyzing breakdown of the neurotransmitter acetylcholine (Ach), which may explain peripheral neuropathy 148. Studies have shown that Tl concentrations in the brain are lower than in other parts of the body 149, 150 and that the highest concentrations in the brain are in the hypothalamus 150. Tl + interferes with a host of K +-dependent processes because of similarities in size and the univalent nature of the two ions; one of the affected processes is ATP generation 142, 149, 151. At the cellular level, higher levels of Tl have been shown to cause a decrease in ATP production, increase in ROS formation, glutathione oxidation, and decreases in dopamine and serotonin levels in the brain 142, 151, 152. Owing to available treatments for this xenobiotic metal and lack of major risk of exposure to the general public, clarity in signaling pathways remains an issue. Furthermore, the complicated symptoms may cause misdiagnosis of Tl poisoning, which points to the need for health professionals to be more aware of the features of Tl-induced poisoning and neurotoxicity 153.

Neurotoxicity induced by metal mixture

The neurotoxicity of metals is usually studied on an individual metal basis. However, the fact is that we are exposed to an environment of mixed metals, which makes it more complicated to study. It is noteworthy that changes in the level of one metal may have significant effect on the homeostasis of other metals, given that various metals (such as Mn, Fe, Cd, Cu, and Zn) are transported by shared transporters or controlled by overlapping signaling pathways. There are limited studies focusing on the combined effect of mixed metal exposure. The neurotoxicity of Pb with other metals (As, Cd, Hg, and Mn) is well studied 154. Prenatal exposure to Pb and As tends to increase the probability of intellectual disability when compared with exposure to a single metal 155. High Pb levels might affect mental and psychomotor development in children with high prenatal Cd exposure 154, 156. Co-exposure to high levels of Pb and Mn together in the prenatal period led to larger deficits in cognition and language development in children at two years of age compared with single-metal exposure 157. Pb exposure was associated with lower IQ scores but only among children with high blood Mn levels 158. In contrast to the synergetic effect between Pb and As, Pb along with Cd, Mn, or Hg exposure tends to work in an antagonistic way, given that the combined effect on cognitive deficits caused by MeHg and Pb exposure was less than additive 159.

In rodents, it has been reported that co-administration of two metals might increase the retention and redistribution of individual metals 160. Co-exposure of Se and Hg increased the retention of both metals and resulted in a redistribution of Hg in the blood and organs 160. Chandra et al. reported that oral intake of Mn and intraperitoneal administration of Pb in rats resulted in alternations in motor activity, learning ability, and biogenic amine levels and Pb levels in the brain, which were more severe than in rats exposed to either Mn or Pb alone 161. Similarly, rat brain weight decreased to a larger degree under conditions of co-exposure to both Mn and Pb than with either metal alone 161. An interaction of As/Pb has been reported to affect the central monaminergic systems in mice. The As/Pb mixture enhanced Pb accumulation but reduced As accumulation in the brain, decreased norepinephrine levels in the hippocampus, and increased serotonin levels in the midbrain and frontal cortex, when compared with single-metal exposure 162. In rats with oral consumption of mining waste (containing As, Cd, Mn, and Pb), accumulation of As and Mn was found in the brain, and dopamine release decreased with a long-standing polarization, when compared with the control 163. Mn may exacerbate the well-documented neurotoxic effects of Pb among children, particularly at younger ages 154. The metal mixture (As, Mn, and Pb) significantly decreased rat motor parameters compared with the single-metal exposure 164. Given that humans are exposed to multiple metals simultaneously in real life and neurotoxicity is commonly accompanied with metal overexposure, more studies are needed to investigate the health impacts of metal mixture in the near future to better understand their synergetic or antagonistic effect.

Treatment for metal-induced neurotoxicity

Upon occurrence of metal poisoning, patients should be transferred out of the exposing environment first, followed by gastrointestinal decontamination. For example, a rapid decrease in blood plasma Mn levels has been noticed with discontinued Mn supplementation in children with cholestasis receiving total parental nutrition 165. However, this therapy might not work well for patients with chronic metal exposure, given that metals have already accumulated in the nervous system, bones, and other tissues rather than in the plasma. Currently, chelation therapy is a common treatment to remove additional metals in the body for both chronic and acute metal poisoning. Chelators include British antilewisite (BAL), succimer (DMSA), Prussian blue, calcium disodium edetate (CaNa 2EDTA), and D-Penicillamine (Cuprimine) 166. However, the chelators themselves may have adverse effects, such as headache, fatigue, renal failure, nasal congestion, gastrointestinal side effects, and life-threatening hypocalcemia, to name a few 166. The specificity of these chelators and the dosage to use are the major concerns when performing chelation therapy. The discovery of specific metal exporters provides novel therapeutics for metal-induced neurotoxicity. For example, SLC30A10 is a newly identified Mn transporter facilitating efflux of excessive intracellular Mn; patients with mutations in the gene presented with dystonia, hypermanganesemia, parkinsonism, and manganism 56, 77, 78, 167. Although a study of its complete substrates has not been finished, this protein seems to transport Mn exclusively 167, 168. Pharmaceutical compounds enhancing the exporting activity of SLC30A10 will promote specifically Mn efflux but leave other metals untouched. This can bypass the side effects caused by chelation to a great degree. Unfortunately, specific transporters for different metals like SLC30A10 for Mn remain largely unknown. Future studies to identify metal-specific transporters are in great need to design therapeutics to treat metal-induced toxicity.

Conclusions and future directions

Metals play an important role in our daily life as they are widely involved in numerous enzymatic activities. Some of them are essential at trace amounts; however, excessive amounts in the human body usually result in neurotoxicity. AD, ALS, autism, and PD are commonly associated with metal overexposure. Once metals have accumulated in the nervous system, oxidative stress, mitochondrial dysfunction, and protein misfolding are the most common deficits associated with metal-induced toxicity 613. Once injured, neurons have to expend greater energy to synthesize neurotransmitters and maintain homeostasis. The increased burden combined with the neurotoxicity may lead to neuronal death. When some neurons are lost, the job has to be passed on to other neurons, initiating a vicious cycle of toxicity. Given that the nervous system does not regenerate as well as other systems do, the neurodegeneration and impairments usually become progressive with age, as typically seen in AD and PD. With the increase of lifespan among the general population, there is arguably a longer duration of exposure to greater levels of metals for individuals and potential increase in frequency of occurrence of neurological diseases. Accordingly, there is a growing demand to investigate the neurotoxicity resulting from metal exposure. Future studies need to focus more on the joint effect of metal mixture exposure, identifying specific transporters of each metal as well as developing target-specific therapeutics for patients with metal poisoning.

Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

  • Anumantha Kanthasamy, Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA

  • Anthony White, Department of Pathology, University of Melbourne, Parkville, Victoria, Australia

  • George Perry, Neuroscience Institute, University of Texas at San Antonio, San Antonio, Texas, USA

Funding Statement

The preparation of this manuscript was supported by National Institutes of Health grants NIEHS R01 10563, NIEHS R01 07331, and 1R01 ES020852.

[version 1; referees: 3 approved]

References

  • 1. Chen P, Parmalee N, Aschner M: Genetic factors and manganese-induced neurotoxicity. Front Genet. 2014;5:265. 10.3389/fgene.2014.00265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Banci L: Metallomics and the Cell. Dordrecht: Springer Netherlands;2013; 12 10.1007/978-94-007-5561-1 [DOI] [Google Scholar]
  • 3. Desai V, Kaler SG: Role of copper in human neurological disorders. Am J Clin Nutr. 2008;88(3):855S–8S. [DOI] [PubMed] [Google Scholar]
  • 4. Rangarajan S, D'Souza GA: Restless legs syndrome in Indian patients having iron deficiency anemia in a tertiary care hospital. Sleep Med. 2007;8(3):247–51. 10.1016/j.sleep.2006.10.004 [DOI] [PubMed] [Google Scholar]
  • 5. Yager JY, Hartfield DS: Neurologic manifestations of iron deficiency in childhood. Pediatr Neurol. 2002;27(2):85–92. 10.1016/S0887-8994(02)00417-4 [DOI] [PubMed] [Google Scholar]
  • 6. Wright RO, Baccarelli A: Metals and neurotoxicology. J Nutr. 2007;137(12):2809–13. [DOI] [PubMed] [Google Scholar]
  • 7. Angeli S, Barhydt T, Jacobs R, et al. : Manganese disturbs metal and protein homeostasis in Caenorhabditis elegans. Metallomics. 2014;6(10):1816–23. 10.1039/c4mt00168k [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Zhang J, Cao R, Cai T, et al. : The role of autophagy dysregulation in manganese-induced dopaminergic neurodegeneration. Neurotox Res. 2013;24(4):478–90. 10.1007/s12640-013-9392-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Seo YA, Li Y, Wessling-Resnick M: Iron depletion increases manganese uptake and potentiates apoptosis through ER stress. Neurotoxicology. 2013;38:67–73. 10.1016/j.neuro.2013.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Gunter TE, Gerstner B, Lester T, et al. : An analysis of the effects of Mn 2+ on oxidative phosphorylation in liver, brain, and heart mitochondria using state 3 oxidation rate assays. Toxicol Appl Pharmacol. 2010;249(1):65–75. 10.1016/j.taap.2010.08.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Malecki EA: Manganese toxicity is associated with mitochondrial dysfunction and DNA fragmentation in rat primary striatal neurons. Brain Res Bull. 2001;55(2):225–8. 10.1016/S0361-9230(01)00456-7 [DOI] [PubMed] [Google Scholar]
  • 12. Bondy SC, Guo-Ross SX, Pien J: Mechanisms underlying the aluminum-induced potentiation of the pro-oxidant properties of transition metals. Neurotoxicology. 1998;19(1):65–71. [PubMed] [Google Scholar]
  • 13. Strong MJ, Garruto RM, Joshi JG, et al. : Can the mechanisms of aluminum neurotoxicity be integrated into a unified scheme? J Toxicol Environ Health. 1996;48(6):599–613. 10.1080/009841096161096 [DOI] [PubMed] [Google Scholar]
  • 14. Shaw CA, Tomljenovic L: Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res. 2013;56(2–3):304–16. 10.1007/s12026-013-8403-1 [DOI] [PubMed] [Google Scholar]
  • 15. Authier FJ, Cherin P, Creange A, et al. : Central nervous system disease in patients with macrophagic myofasciitis. Brain. 2001;124(Pt 5):974–83. 10.1093/brain/124.5.974 [DOI] [PubMed] [Google Scholar]
  • 16. Strausak D, Mercer JF, Dieter HH, et al. : Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res Bull. 2001;55(2):175–85. 10.1016/S0361-9230(01)00454-3 [DOI] [PubMed] [Google Scholar]
  • 17. Okuda B, Iwamoto Y, Tachibana H, et al. : Parkinsonism after acute cadmium poisoning. Clin Neurol Neurosurg. 1997;99(4):263–5. 10.1016/S0303-8467(97)00090-5 [DOI] [PubMed] [Google Scholar]
  • 18. Chen P, Chakraborty S, Peres TV, et al. : Manganese-induced Neurotoxicity: From C. elegans to Humans. Toxicol Res (Camb). 2015;4(2):191–202. 10.1039/C4TX00127C [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Valensin D, Padula EM, Hecel A, et al. : Specific binding modes of Cu(I) and Ag(I) with neurotoxic domain of the human prion protein. J Inorg Biochem. 2016;155:26–35. 10.1016/j.jinorgbio.2015.11.015 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 20. Ha C, Ryu J, Park CB: Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry. 2007;46(20):6118–25. 10.1021/bi7000032 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 21. Roos PM, Vesterberg O, Nordberg M: Metals in motor neuron diseases. Exp Biol Med (Maywood). 2006;231(9):1481–7. [DOI] [PubMed] [Google Scholar]
  • 22. Rasia RM, Bertoncini CW, Marsh D, et al. : Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci U S A. 2005;102(12):4294–9. 10.1073/pnas.0407881102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Isani G, Carpenè E: Metallothioneins, unconventional proteins from unconventional animals: a long journey from nematodes to mammals. Biomolecules. 2014;4(2):435–57. 10.3390/biom4020435 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Fox JH, Kama JA, Lieberman G, et al. : Mechanisms of copper ion mediated Huntington's disease progression. PLoS One. 2007;2(3):e334. 10.1371/journal.pone.0000334 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 25. Thackray AM, Knight R, Haswell SJ, et al. : Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochem J. 2002;362(Pt 1):253–8. 10.1042/bj3620253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Wong BS, Chen SG, Colucci M, et al. : Aberrant metal binding by prion protein in human prion disease. J Neurochem. 2001;78(6):1400–8. 10.1046/j.1471-4159.2001.00522.x [DOI] [PubMed] [Google Scholar]
  • 27. Quaglio E, Chiesa R, Harris DA: Copper converts the cellular prion protein into a protease-resistant species that is distinct from the scrapie isoform. J Biol Chem. 2001;276(14):11432–8. 10.1074/jbc.M009666200 [DOI] [PubMed] [Google Scholar]
  • 28. Pass R, Frudd K, Barnett JP, et al. : Prion infection in cells is abolished by a mutated manganese transporter but shows no relation to zinc. Mol Cell Neurosci. 2015;68:186–93. 10.1016/j.mcn.2015.08.004 [DOI] [PubMed] [Google Scholar]
  • 29. Hijazi N, Shaked Y, Rosenmann H, et al. : Copper binding to PrP C may inhibit prion disease propagation. Brain Res. 2003;993(1–2):192–200. 10.1016/j.brainres.2003.09.014 [DOI] [PubMed] [Google Scholar]
  • 30. Biasiotto G, Di Lorenzo D, Archetti S, et al. : Iron and Neurodegeneration: Is Ferritinophagy the Link? Mol Neurobiol. 2015;1–33. 10.1007/s12035-015-9473-y [DOI] [PubMed] [Google Scholar]
  • 31. Sheftel AD, Mason AB, Ponka P: The long history of iron in the Universe and in health and disease. Biochim Biophys Acta. 2012;1820(3):161–87. 10.1016/j.bbagen.2011.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Chatterjee S, Sarkar S, Bhattacharya S: Toxic metals and autophagy. Chem Res Toxicol. 2014;27(11):1887–900. 10.1021/tx500264s [DOI] [PubMed] [Google Scholar]
  • 33. Arber CE, Li A, Houlden H, et al. : Insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. Neuropathol Appl Neurobiol. 2015. 10.1111/nan.12242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Akar E, Ünalp A, Diniz G, et al. : Investigation of iron's neurotoxicity during cerebral maturation in the neonatal rat model of haemolysis. Folia Neuropathol. 2015;53(3):262–9. 10.5114/fn.2015.54623 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 35. Nohl H, Kozlov AV, Gille L, et al. : Cell respiration and formation of reactive oxygen species: facts and artefacts. Biochem Soc Trans. 2003;31(Pt 6):1308–11. 10.1042/bst0311308 [DOI] [PubMed] [Google Scholar]
  • 36. Salvador GA, Uranga RM, Giusto NM: Iron and mechanisms of neurotoxicity. Int J Alzheimers Dis. 2010;2011: 720658. 10.4061/2011/720658 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Shen XM, Dryhurst G: Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. Chem Res Toxicol. 1998;11(7):824–37. 10.1021/tx980036t [DOI] [PubMed] [Google Scholar]
  • 38. Park J, Lee DG, Kim B, et al. : Iron overload triggers mitochondrial fragmentation via calcineurin-sensitive signals in HT-22 hippocampal neuron cells. Toxicology. 2015;337:39–46. 10.1016/j.tox.2015.08.009 [DOI] [PubMed] [Google Scholar]
  • 39. Zucca FA, Segura-Aguilar J, Ferrari E, et al. : Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol. 2015; pii: S0301-0082(15)00101-X. 10.1016/j.pneurobio.2015.09.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Greenough MA, Camakaris J, Bush AI: Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int. 2013;62(5):540–55. 10.1016/j.neuint.2012.08.014 [DOI] [PubMed] [Google Scholar]
  • 41. Meyer E, Kurian MA, Hayflick SJ: Neurodegeneration with Brain Iron Accumulation: Genetic Diversity and Pathophysiological Mechanisms. Annu Rev Genomics Hum Genet. 2015;16:257–79. 10.1146/annurev-genom-090314-025011 [DOI] [PubMed] [Google Scholar]
  • 42. Doorn JM, Kruer MC: Newly characterized forms of neurodegeneration with brain iron accumulation. Curr Neurol Neurosci Rep. 2013;13(12):413. 10.1007/s11910-013-0413-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Pyatigorskaya N, Sharman M, Corvol JC, et al. : High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry. Mov Disord. 2015;30(8):1077–84. 10.1002/mds.26218 [DOI] [PubMed] [Google Scholar]
  • 44. Febbraro F, Giorgi M, Caldarola S, et al. : α-Synuclein expression is modulated at the translational level by iron. Neuroreport. 2012;23(9):576–80. 10.1097/WNR.0b013e328354a1f0 [DOI] [PubMed] [Google Scholar]
  • 45. Uversky VN, Li J, Fink AL: Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem. 2001;276(47):44284–96. 10.1074/jbc.M105343200 [DOI] [PubMed] [Google Scholar]
  • 46. Ayton S, Lei P, Bush AI: Metallostasis in Alzheimer's disease. Free Radic Biol Med. 2013;62:76–89. 10.1016/j.freeradbiomed.2012.10.558 [DOI] [PubMed] [Google Scholar]
  • 47. Banerjee P, Sahoo A, Anand S, et al. : Multiple mechanisms of iron-induced amyloid beta-peptide accumulation in SHSY5Y cells: protective action of negletein. Neuromolecular Med. 2014;16(4):787–98. 10.1007/s12017-014-8328-4 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 48. Liu B, Moloney A, Meehan S, et al. : Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem. 2011;286(6):4248–56. 10.1074/jbc.M110.158980 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 49. Bartzokis G, Cummings J, Perlman S, et al. : Increased basal ganglia iron levels in Huntington disease. Arch Neurol. 1999;56(5):569–74. 10.1001/archneur.56.5.569 [DOI] [PubMed] [Google Scholar]
  • 50. Lumsden AL, Henshall TL, Dayan S, et al. : Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet. 2007;16(16):1905–20. 10.1093/hmg/ddm138 [DOI] [PubMed] [Google Scholar]
  • 51. Kwan JY, Jeong SY, Van Gelderen P, et al. : Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology. PLoS One. 2012;7(4):e35241. 10.1371/journal.pone.0035241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Yu J, Qi F, Wang N, et al. : Increased iron level in motor cortex of amyotrophic lateral sclerosis patients: an in vivo MR study. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5–6):357–61. 10.3109/21678421.2014.906618 [DOI] [PubMed] [Google Scholar]
  • 53. Lee JK, Shin JH, Gwag BJ, et al. : Iron accumulation promotes TACE-mediated TNF-α secretion and neurodegeneration in a mouse model of ALS. Neurobiol Dis. 2015;80:63–9. 10.1016/j.nbd.2015.05.009 [DOI] [PubMed] [Google Scholar]
  • 54. Hadzhieva M, Kirches E, Wilisch-Neumann A, et al. : Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience. 2013;230:94–101. 10.1016/j.neuroscience.2012.11.021 [DOI] [PubMed] [Google Scholar]
  • 55. Horning KJ, Caito SW, Tipps KG, et al. : Manganese Is Essential for Neuronal Health. Annu Rev Nutr. 2015;35:71–108. 10.1146/annurev-nutr-071714-034419 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Chen P, Chakraborty S, Mukhopadhyay S, et al. : Manganese homeostasis in the nervous system. J Neurochem. 2015;134(4):601–10. 10.1111/jnc.13170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Michalke B, Fernsebner K: New insights into manganese toxicity and speciation. J Trace Elem Med Biol. 2014;28(2):106–16. 10.1016/j.jtemb.2013.08.005 [DOI] [PubMed] [Google Scholar]
  • 58. Gorell JM, Rybicki BA, Cole Johnson C, et al. : Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology. 1999;18(6):303–8. 10.1159/000026225 [DOI] [PubMed] [Google Scholar]
  • 59. Kwakye GF, Paoliello MM, Mukhopadhyay S, et al. : Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features. Int J Environ Res Public Health. 2015;12(7):7519–40. 10.3390/ijerph120707519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Williams M, Todd GD, Roney N, et al. : Toxicological Profile for Manganese. Atlanta (GA): Agency for Toxic Substances and Disease Registry (US);2012. Sep. [PubMed] [Google Scholar]
  • 61. Karki P, Smith K, Johnson J, Jr, et al. : Role of transcription factor yin yang 1 in manganese-induced reduction of astrocytic glutamate transporters: Putative mechanism for manganese-induced neurotoxicity. Neurochem Int. 2015;88:53–9. 10.1016/j.neuint.2014.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Racette BA: Manganism in the 21st century: the Hanninen lecture. Neurotoxicology. 2014;45:201–7. 10.1016/j.neuro.2013.09.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Robison G, Sullivan B, Cannon JR, et al. : Identification of dopaminergic neurons of the substantia nigra pars compacta as a target of manganese accumulation. Metallomics. 2015;7(5):748–55. 10.1039/c5mt00023h [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 64. Rudgalvyte M, Peltonen J, Lakso M, et al. : RNA-Seq Reveals Acute Manganese Exposure Increases Endoplasmic Reticulum Related and Lipocalin mRNAs in Caenorhabditis elegans. J Biochem Mol Toxicol. 2016;30(2):97–105. 10.1002/jbt.21768 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 65. Martinez-Finley EJ, Gavin CE, Aschner M, et al. : Manganese neurotoxicity and the role of reactive oxygen species. Free Radic Biol Med. 2013;62:65–75. 10.1016/j.freeradbiomed.2013.01.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Farina M, Avila DS, da Rocha JB, et al. : Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury. Neurochem Int. 2013;62(5):575–94. 10.1016/j.neuint.2012.12.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Gorojod RM, Alaimo A, Porte Alcon S, et al. : The autophagic- lysosomal pathway determines the fate of glial cells under manganese- induced oxidative stress conditions. Free Radic Biol Med. 2015;87:237–51. 10.1016/j.freeradbiomed.2015.06.034 [DOI] [PubMed] [Google Scholar]
  • 68. Yousefi Babadi V, Sadeghi L, Shirani K, et al. : The toxic effect of manganese on the acetylcholinesterase activity in rat brains. J Toxicol. 2014;2014: 946372. 10.1155/2014/946372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Liang G, Qin H, Zhang L, et al. : Effects of chronic manganese exposure on the learning and memory of rats by observing the changes in the hippocampal cAMP signaling pathway. Food Chem Toxicol. 2015;83:261–7. 10.1016/j.fct.2015.07.005 [DOI] [PubMed] [Google Scholar]
  • 70. Kwik-Uribe C, Smith DR: Temporal responses in the disruption of iron regulation by manganese. J Neurosci Res. 2006;83(8):1601–10. 10.1002/jnr.20836 [DOI] [PubMed] [Google Scholar]
  • 71. Roth JA, Horbinski C, Higgins D, et al. : Mechanisms of manganese-induced rat pheochromocytoma (PC12) cell death and cell differentiation. Neurotoxicology. 2002;23(2):147–57. 10.1016/S0161-813X(01)00077-8 [DOI] [PubMed] [Google Scholar]
  • 72. Harischandra DS, Jin H, Anantharam V, et al. : α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease. Toxicol Sci. 2015;143(2):454–68. 10.1093/toxsci/kfu247 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 73. Anantharam V, Kitazawa M, Wagner J, et al. : Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J Neurosci. 2002;22(5):1738–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Latchoumycandane C, Anantharam V, Kitazawa M, et al. : Protein kinase Cdelta is a key downstream mediator of manganese-induced apoptosis in dopaminergic neuronal cells. J Pharmacol Exp Ther. 2005;313(1):46–55. 10.1124/jpet.104.078469 [DOI] [PubMed] [Google Scholar]
  • 75. Tuschl K, Clayton PT, Gospe SM, Jr, et al. : Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet. 2012;90(3):457–66. 10.1016/j.ajhg.2012.01.018 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 76. Stamelou M, Tuschl K, Chong WK, et al. : Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder. Mov Disord. 2012;27(10):1317–22. 10.1002/mds.25138 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 77. Quadri M, Federico A, Zhao T, et al. : Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012;90(3):467–77. 10.1016/j.ajhg.2012.01.017 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 78. Choi CJ, Anantharam V, Saetveit NJ, et al. : Normal cellular prion protein protects against manganese-induced oxidative stress and apoptotic cell death. Toxicol Sci. 2007;98(2):495–509. 10.1093/toxsci/kfm099 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 79. Choi CJ, Anantharam V, Martin DP, et al. : Manganese upregulates cellular prion protein and contributes to altered stabilization and proteolysis: relevance to role of metals in pathogenesis of prion disease. Toxicol Sci. 2010;115(2):535–46. 10.1093/toxsci/kfq049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Hambidge M: Human zinc deficiency. J Nutr. 2000;130(5S Suppl):1344S–9S. [DOI] [PubMed] [Google Scholar]
  • 81. Mizuno D, Kawahara M: The molecular mechanisms of zinc neurotoxicity and the pathogenesis of vascular type senile dementia. Int J Mol Sci. 2013;14(11):22067–81. 10.3390/ijms141122067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Prasad AS: Impact of the discovery of human zinc deficiency on health. J Am Coll Nutr. 2009;28(3):257–65. 10.1080/07315724.2009.10719780 [DOI] [PubMed] [Google Scholar]
  • 83. Fosmire GJ: Zinc toxicity. Am J Clin Nutr. 1990;51(2):225–7. [DOI] [PubMed] [Google Scholar]
  • 84. Cuajungco MP, Goldstein LE, Nunomura A, et al. : Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem. 2000;275(26):19439–42. 10.1074/jbc.C000165200 [DOI] [PubMed] [Google Scholar]
  • 85. Garai K, Sahoo B, Kaushalya SK, et al. : Zinc lowers amyloid-beta toxicity by selectively precipitating aggregation intermediates. Biochemistry. 2007;46(37):10655–63. 10.1021/bi700798b [DOI] [PubMed] [Google Scholar]
  • 86. Cuajungco MP, Fagét KY: Zinc takes the center stage: its paradoxical role in Alzheimer's disease. Brain Res Brain Res Rev. 2003;41(1):44–56. 10.1016/S0165-0173(02)00219-9 [DOI] [PubMed] [Google Scholar]
  • 87. Jomova K, Vondrakova D, Lawson M, et al. : Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010;345(1–2):91–104. 10.1007/s11010-010-0563-x [DOI] [PubMed] [Google Scholar]
  • 88. Weiss JH, Sensi SL, Koh JY: Zn 2+: a novel ionic mediator of neural injury in brain disease. Trends Pharmacol Sci. 2000;21(10):395–401. 10.1016/S0165-6147(00)01541-8 [DOI] [PubMed] [Google Scholar]
  • 89. Edwardson JA, Candy JM, Ince PG, et al. : Aluminium accumulation, beta-amyloid deposition and neurofibrillary changes in the central nervous system. Ciba Found Symp. 1992;169:165–79; discussion 179–85. [DOI] [PubMed] [Google Scholar]
  • 90. Harrington CR, Wischik CM, McArthur FK, et al. : Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet. 1994;343(8904):993–7. 10.1016/S0140-6736(94)90124-4 [DOI] [PubMed] [Google Scholar]
  • 91. Flendrig JA, Kruis H, Das HA, editors: Aluminium intoxication: the cause of dialysis dementia? Proc Eur Dial Transplant Assoc. 1976. Reference Source [Google Scholar]
  • 92. Wang Z, Wei X, Yang J, et al. : Chronic exposure to aluminum and risk of Alzheimer's disease: A meta-analysis. Neurosci Lett. 2016;610:200–6. 10.1016/j.neulet.2015.11.014 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 93. Lopes MM, Caldas LQA: Young children with austim spectrum disorders: Can aluminium bodyburden cause metabolism disruption? Toxicol Lett. 2011;205(Supplement):S92 10.1016/j.toxlet.2011.05.338 [DOI] [Google Scholar]
  • 94. De Marchi U, Mancon M, Battaglia V, et al. : Influence of reactive oxygen species production by monoamine oxidase activity on aluminum-induced mitochondrial permeability transition. Cell Mol Life Sci. 2004;61(19–20):2664–71. 10.1007/s00018-004-4236-3 [DOI] [PubMed] [Google Scholar]
  • 95. Murakami K, Yoshino M: Aluminum decreases the glutathione regeneration by the inhibition of NADP-isocitrate dehydrogenase in mitochondria. J Cell Biochem. 2004;93(6):1267–71. 10.1002/jcb.20261 [DOI] [PubMed] [Google Scholar]
  • 96. Niu PY, Niu Q, Zhang QL, et al. : Aluminum impairs rat neural cell mitochondria in vitro. Int J Immunopathol Pharmacol. 2005;18(4):683–9. [DOI] [PubMed] [Google Scholar]
  • 97. Prakash C, Soni M, Kumar V: Mitochondrial oxidative stress and dysfunction in arsenic neurotoxicity: A review. J Appl Toxicol. 2016;36(2):179–88. 10.1002/jat.3256 [DOI] [PubMed] [Google Scholar]
  • 98. Tolins M, Ruchirawat M, Landrigan P: The developmental neurotoxicity of arsenic: cognitive and behavioral consequences of early life exposure. Ann Glob Health. 2014;80(4):303–14. 10.1016/j.aogh.2014.09.005 [DOI] [PubMed] [Google Scholar]
  • 99. Breuer C, Oh J, Nolkemper D, et al. : Successful detoxification and liver transplantation in a severe poisoning with a chemical wood preservative containing chromium, copper, and arsenic. Transplantation. 2015;99(4):e29–30. 10.1097/TP.0000000000000654 [DOI] [PubMed] [Google Scholar]
  • 100. McClintock TR, Chen Y, Bundschuh J, et al. : Arsenic exposure in Latin America: biomarkers, risk assessments and related health effects. Sci Total Environ. 2012;429:76–91. 10.1016/j.scitotenv.2011.08.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101. Aung KH, Tsukahara S, Maekawa F, et al. : Role of Environmental Chemical Insult in Neuronal Cell Death and Cytoskeleton Damage. Biol Pharm Bull. 2015;38(8):1109–12. 10.1248/bpb.b14-00890 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 102. Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B: Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci. 2015;9:124. 10.3389/fncel.2015.00124 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Zarazúa S, Bürger S, Delgado JM, et al. : Arsenic affects expression and processing of amyloid precursor protein (APP) in primary neuronal cells overexpressing the Swedish mutation of human APP. Int J Dev Neurosci. 2011;29(4):389–96. 10.1016/j.ijdevneu.2011.03.004 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 104. DeFuria J, Shea TB: Arsenic inhibits neurofilament transport and induces perikaryal accumulation of phosphorylated neurofilaments: roles of JNK and GSK-3beta. Brain Res. 2007;1181:74–82. 10.1016/j.brainres.2007.04.019 [DOI] [PubMed] [Google Scholar]
  • 105. Luevano J, Damodaran C: A review of molecular events of cadmium-induced carcinogenesis. J Environ Pathol Toxicol Oncol. 2014;33(3):183–94. 10.1615/JEnvironPatholToxicolOncol.2014011075 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Wang B, Du Y: Cadmium and its neurotoxic effects. Oxid Med Cell Longev. 2013;2013: 898034. 10.1155/2013/898034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Bishak YK, Payahoo L, Osatdrahimi A, et al. : Mechanisms of cadmium carcinogenicity in the gastrointestinal tract. Asian Pac J Cancer Prev. 2015;16(1):9–21. 10.7314/APJCP.2015.16.1.9 [DOI] [PubMed] [Google Scholar]
  • 108. Jiang LF, Yao TM, Zhu ZL, et al. : Impacts of Cd(II) on the conformation and self-aggregation of Alzheimer's tau fragment corresponding to the third repeat of microtubule-binding domain. Biochim Biophys Acta. 2007;1774(11):1414–21. 10.1016/j.bbapap.2007.08.014 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 109. Chow ES, Hui MN, Lin CC, et al. : Cadmium inhibits neurogenesis in zebrafish embryonic brain development. Aquat Toxicol. 2008;87(3):157–69. 10.1016/j.aquatox.2008.01.019 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 110. López E, Figueroa S, Oset-Gasque MJ, et al. : Apoptosis and necrosis: two distinct events induced by cadmium in cortical neurons in culture. Br J Pharmacol. 2003;138(5):901–11. 10.1038/sj.bjp.0705111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111. Radio NM, Breier JM, Shafer TJ, et al. : Assessment of chemical effects on neurite outgrowth in PC12 cells using high content screening. Toxicol Sci. 2008;105(1):106–18. 10.1093/toxsci/kfn114 [DOI] [PubMed] [Google Scholar]
  • 112. Mason LH, Harp JP, Han DY: Pb neurotoxicity: neuropsychological effects of lead toxicity. Biomed Res Int. 2014;2014: 840547. 10.1155/2014/840547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Struzyñska L, Bubko I, Walski M, et al. : Astroglial reaction during the early phase of acute lead toxicity in the adult rat brain. Toxicology. 2001;165(2–3):121–31. 10.1016/S0300-483X(01)00415-2 [DOI] [PubMed] [Google Scholar]
  • 114. Audesirk G: Electrophysiology of lead intoxication: effects on voltage-sensitive ion channels. Neurotoxicology. 1993;14(2–3):137–47. [PubMed] [Google Scholar]
  • 115. Zheng W, Aschner M, Ghersi-Egea JF: Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol. 2003;192(1):1–11. 10.1016/S0041-008X(03)00251-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Selvín-Testa A, Capani F, Loidl CF, et al. : The nitric oxide synthase expression of rat cortical and hippocampal neurons changes after early lead exposure. Neurosci Lett. 1997;236(2):75–8. 10.1016/S0304-3940(97)00736-2 [DOI] [PubMed] [Google Scholar]
  • 117. Nava-Ruiz C, Méndez-Armenta M, Ríos C: Lead neurotoxicity: effects on brain nitric oxide synthase. J Mol Histol. 2012;43(5):553–63. 10.1007/s10735-012-9414-2 [DOI] [PubMed] [Google Scholar]
  • 118. Winneke G, Lilienthal H, Krämer U: The neurobehavioural toxicology and teratology of lead. Arch Toxicol Suppl. 1996;18:57–70. 10.1007/978-3-642-61105-6_7 [DOI] [PubMed] [Google Scholar]
  • 119. Pocock SJ, Smith M, Baghurst P: Environmental lead and children's intelligence: a systematic review of the epidemiological evidence. BMJ. 1994;309(6963):1189–97. 10.1136/bmj.309.6963.1189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120. Baker EL, Feldman RG, White RF, et al. : The role of occupational lead exposure in the genesis of psychiatric and behavioral disturbances. Acta Psychiatr Scand Suppl. 1983;303:38–48. 10.1111/j.1600-0447.1983.tb00940.x [DOI] [PubMed] [Google Scholar]
  • 121. Needleman HL, Schell A, Bellinger D, et al. : The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report. N Engl J Med. 1990;322(2):83–8. 10.1056/NEJM199001113220203 [DOI] [PubMed] [Google Scholar]
  • 122. Campbell TF, Needleman HL, Riess JA, et al. : Bone lead levels and language processing performance. Dev Neuropsychol. 2000;18(2):171–86. 10.1207/S15326942DN1802_2 [DOI] [PubMed] [Google Scholar]
  • 123. Stewart WF, Schwartz BS: Effects of lead on the adult brain: a 15-year exploration. Am J Ind Med. 2007;50(10):729–39. 10.1002/ajim.20434 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 124. Parkinson DK, Ryan C, Bromet EJ, et al. : A psychiatric epidemiologic study of occupational lead exposure. Am J Epidemiol. 1986;123(2):261–9. [DOI] [PubMed] [Google Scholar]
  • 125. Li WC, Tse HF: Health risk and significance of mercury in the environment. Environ Sci Pollut Res Int. 2015;22(1):192–201. 10.1007/s11356-014-3544-x [DOI] [PubMed] [Google Scholar]
  • 126. Parks JM, Johs A, Podar M, et al. : The genetic basis for bacterial mercury methylation. Science. 2013;339(6125):1332–5. 10.1126/science.1230667 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 127. Sheehan MC, Burke TA, Navas-Acien A, et al. : Global methylmercury exposure from seafood consumption and risk of developmental neurotoxicity: a systematic review. Bull World Health Organ. 2014;92(4):254–269F. 10.2471/BLT.12.116152 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128. Aschner M, Aschner JL: Mercury neurotoxicity: mechanisms of blood-brain barrier transport. Neurosci Biobehav Rev. 1990;14(2):169–76. 10.1016/S0149-7634(05)80217-9 [DOI] [PubMed] [Google Scholar]
  • 129. Kerper LE, Ballatori N, Clarkson TW: Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol. 1992;262(5 Pt 2):R761–5. [DOI] [PubMed] [Google Scholar]
  • 130. Hong YS, Kim YM, Lee KE: Methylmercury exposure and health effects. J Prev Med Public Health. 2012;45(6):353–63. 10.3961/jpmph.2012.45.6.353 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131. Davis LE, Kornfeld M, Mooney HS, et al. : Methylmercury poisoning: long-term clinical, radiological, toxicological, and pathological studies of an affected family. Ann Neurol. 1994;35(6):680–8. 10.1002/ana.410350608 [DOI] [PubMed] [Google Scholar]
  • 132. Tiernan CT, Edwin EA, Hawong HY, et al. : Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase. Toxicol Sci. 2015;144(2):347–56. 10.1093/toxsci/kfv001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133. Tamm C, Duckworth JK, Hermanson O, et al. : Methylmercury inhibits differentiation of rat neural stem cells via Notch signalling. Neuroreport. 2008;19(3):339–43. 10.1097/WNR.0b013e3282f50ca4 [DOI] [PubMed] [Google Scholar]
  • 134. Petroni D, Tsai J, Agrawal K, et al. : Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells. Environ Toxicol. 2012;27(9):549–55. 10.1002/tox.20672 [DOI] [PubMed] [Google Scholar]
  • 135. Sadiq S, Ghazala Z, Chowdhury A, et al. : Metal toxicity at the synapse: presynaptic, postsynaptic, and long-term effects. J Toxicol. 2012;2012: 132671. 10.1155/2012/132671 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136. Chang SH, Lee HJ, Kang B, et al. : Methylmercury induces caspase-dependent apoptosis and autophagy in human neural stem cells. J Toxicol Sci. 2013;38(6):823–31. 10.2131/jts.38.823 [DOI] [PubMed] [Google Scholar]
  • 137. Yuntao F, Chenjia G, Panpan Z, et al. : Role of autophagy in methylmercury-induced neurotoxicity in rat primary astrocytes. Arch Toxicol. 2016;90(2):333–45. 10.1007/s00204-014-1425-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138. Rice KM, Walker EM, Jr, Wu M, et al. : Environmental mercury and its toxic effects. J Prev Med Public Health. 2014;47(2):74–83. 10.3961/jpmph.2014.47.2.74 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139. Kim DK, Park JD, Choi BS: Mercury-induced amyloid-beta (Aβ) accumulation in the brain is mediated by disruption of Aβ transport. J Toxicol Sci. 2014;39(4):625–35. 10.2131/jts.39.625 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 140. Ser PH, Watanabe C: Fish advisories in the USA and Japan: risk communication and public awareness of a common idea with different backgrounds. Asia Pac J Clin Nutr. 2012;21(4):487–94. [PubMed] [Google Scholar]
  • 141. Budtz-Jørgensen E, Grandjean P, Weihe P: Separation of risks and benefits of seafood intake. Environ Health Perspect. 2007;115(3):323–7. 10.1289/ehp.9738 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142. Galván-Arzate S, Santamaría A: Thallium toxicity. Toxicol Lett. 1998;99(1):1–13. 10.1016/S0378-4274(98)00126-X [DOI] [PubMed] [Google Scholar]
  • 143. Cvjetko P, Cvjetko I, Pavlica M: Thallium toxicity in humans. Arh Hig Rada Toksikol. 2010;61(1):111–9. 10.2478/10004-1254-61-2010-1976 [DOI] [PubMed] [Google Scholar]
  • 144. Saha A: Thallium toxicity: A growing concern. Indian J Occup Environ Med. 2005;9(2):53–56. 10.4103/0019-5278.16741 [DOI] [Google Scholar]
  • 145. Zhao G, Ding M, Zhang B, et al. : Clinical manifestations and management of acute thallium poisoning. Eur Neurol. 2008;60(6):292–7. 10.1159/000157883 [DOI] [PubMed] [Google Scholar]
  • 146. Pelclová D, Urban P, Ridzon P, et al. : Two-year follow-up of two patients after severe thallium intoxication. Hum Exp Toxicol. 2009;28(5):263–72. 10.1177/0960327109106487 [DOI] [PubMed] [Google Scholar]
  • 147. McCormack J, McKinney W: Thallium poisoning in group assassination attempt. Postgrad Med. 1983;74(6):239–41, 244. [DOI] [PubMed] [Google Scholar]
  • 148. Repetto G, Sanz P, Repetto M: In vitro effects of thallium on mouse neuroblastoma cells. Toxicol In Vitro. 1994;8(4):609–11. 10.1016/0887-2333(94)90028-0 [DOI] [PubMed] [Google Scholar]
  • 149. Ibrahim D, Froberg B, Wolf A, et al. : Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med. 2006;26(1):67–97, viii. 10.1016/j.cll.2006.02.003 [DOI] [PubMed] [Google Scholar]
  • 150. Ríos C, Galván-Arzate S, Tapia R: Brain regional thallium distribution in rats acutely intoxicated with Tl 2SO 4. Arch Toxicol. 1989;63(1):34–7. 10.1007/BF00334631 [DOI] [PubMed] [Google Scholar]
  • 151. Eskandari MR, Mashayekhi V, Aslani M, et al. : Toxicity of thallium on isolated rat liver mitochondria: the role of oxidative stress and MPT pore opening. Environ Toxicol. 2015;30(2):232–41. 10.1002/tox.21900 [DOI] [PubMed] [Google Scholar]
  • 152. Hasan M, Ali SF, Tariq M: Levels of dopamine, norepinephrine and 5-hydroxytryptamine in different regions of the rat brain in thallium toxicosis. Acta Pharmacol Toxicol (Copenh). 1978;43(3):169–73. 10.1111/j.1600-0773.1978.tb02251.x [DOI] [PubMed] [Google Scholar]
  • 153. Li JM, Wang W, Lei S, et al. : Misdiagnosis and long-term outcome of 13 patients with acute thallium poisoning in China. Clin Toxicol (Phila). 2014;52(3):181–6. 10.3109/15563650.2014.892123 [DOI] [PubMed] [Google Scholar]
  • 154. Sanders AP, Claus Henn B, Wright RO: Perinatal and Childhood Exposure to Cadmium, Manganese, and Metal Mixtures and Effects on Cognition and Behavior: A Review of Recent Literature. Curr Environ Health Rep. 2015;2(3):284–94. 10.1007/s40572-015-0058-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155. McDermott S, Wu J, Cai B, et al. : Probability of intellectual disability is associated with soil concentrations of arsenic and lead. Chemosphere. 2011;84(1):31–8. 10.1016/j.chemosphere.2011.02.088 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 156. Kim Y, Ha E, Park H, et al. : Prenatal lead and cadmium co-exposure and infant neurodevelopment at 6 months of age: the Mothers and Children's Environmental Health (MOCEH) study. Neurotoxicology. 2013;35:15–22. 10.1016/j.neuro.2012.11.006 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 157. Lin CC, Chen YC, Su FC, et al. : In utero exposure to environmental lead and manganese and neurodevelopment at 2 years of age. Environ Res. 2013;123:52–7. 10.1016/j.envres.2013.03.003 [DOI] [PubMed] [Google Scholar]
  • 158. Kim Y, Kim BN, Hong YC, et al. : Co-exposure to environmental lead and manganese affects the intelligence of school-aged children. Neurotoxicology. 2009;30(4):564–71. 10.1016/j.neuro.2009.03.012 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 159. Yorifuji T, Debes F, Weihe P, et al. : Prenatal exposure to lead and cognitive deficit in 7- and 14-year-old children in the presence of concomitant exposure to similar molar concentration of methylmercury. Neurotoxicol Teratol. 2011;33(2):205–11. 10.1016/j.ntt.2010.09.004 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 160. Kalia K, Murthy RC, Chandra SV: Tissue disposition of 54Mn in lead pretreated rats. Ind Health. 1984;22(1):49–52. 10.2486/indhealth.22.49 [DOI] [PubMed] [Google Scholar]
  • 161. Chandra SV, Murthy RC, Saxena DK, et al. : Effects of pre- and postnatal combined exposure to Pb and Mn on brain development in rats. Ind Health. 1983;21(4):273–9. 10.2486/indhealth.21.273 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 162. Mejía JJ, Díaz-Barriga F, Calderón J, et al. : Effects of lead-arsenic combined exposure on central monoaminergic systems. Neurotoxicol Teratol. 1997;19(6):489–97. 10.1016/S0892-0362(97)00066-4 [DOI] [PubMed] [Google Scholar]
  • 163. Rodríguez VM, Dufour L, Carrizales L, et al. : Effects of oral exposure to mining waste on in vivo dopamine release from rat striatum. Environ Health Perspect. 1998;106(8):487–91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164. Andrade V, Mateus ML, Batoréu MC, et al. : Changes in rat urinary porphyrin profiles predict the magnitude of the neurotoxic effects induced by a mixture of lead, arsenic and manganese. Neurotoxicology. 2014;45:168–77. 10.1016/j.neuro.2014.10.009 [DOI] [PubMed] [Google Scholar]
  • 165. Hambidge KM, Sokol RJ, Fidanza SJ, et al. : Plasma manganese concentrations in infants and children receiving parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989;13(2):168–71. 10.1177/0148607189013002168 [DOI] [PubMed] [Google Scholar]
  • 166. Jang DH, Hoffman RS: Heavy metal chelation in neurotoxic exposures. Neurol Clin. 2011;29(3):607–22. 10.1016/j.ncl.2011.05.002 [DOI] [PubMed] [Google Scholar]
  • 167. Leyva-Illades D, Chen P, Zogzas CE, et al. : SLC30A10 is a cell surface-localized manganese efflux transporter, and parkinsonism-causing mutations block its intracellular trafficking and efflux activity. J Neurosci. 2014;34(42):14079–95. 10.1523/JNEUROSCI.2329-14.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168. Chen P, Bowman AB, Mukhopadhyay S, et al. : SLC30A10: A novel manganese transporter. Worm. 2015;4(3):e1042648. 10.1080/21624054.2015.1042648 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from F1000Research are provided here courtesy of F1000 Research Ltd

RESOURCES